In brief
In an unprecedented move, the FDA has sent over 100 warning letters to telehealth companies like Hims & Hers for promoting unverified versions of prescription drugs, particularly those related to weight loss. The agency's letters, which emphasize the need for truthful advertisements, follow a directive from President Trump to ensure pharmaceutical ads comply with legal standards. Hims has been called out for misrepresenting its products as equivalent to FDA-approved drugs, raising serious concerns about consumer safety and ethical advertising practices.
WASHINGTON (AP) — For the first time, federal health officials are taking aim at telehealth companies promoting unofficial versions of prescription drugs — including popular weight loss medications — as part of the Trump administration’s crackdown on pharmaceutical advertising.The Food and Drug Administration on Tuesday posted more than 100 letters to various drug and online prescribing companies, including Hims & Hers, which has built a multibillion-dollar business centered around lower-cost versions of blockbuster obesity injections.The FDA warned the company to remove “false and misleading” promotional statements from its website, including language claiming that its customized products contain “the same active ingredient” as FDA-approved drugs Wegovy and Ozempic. The formulations cited by regulators are produced by specialty compounding pharmacies and aren’t reviewed by the FDA.“Your claims imply that your products are the same as an FDA-approved product when they are not,” states the warning letter, dated Sept. 9.It’s the first FDA attempt to directly police online platforms like Hims, which have long argued they’re not subject to drug advertising rules.A memo signed by President Donald Trump last week directed Health Secretary Robert F. Kennedy Jr. and the FDA to ensure that pharmaceutical ads on TV, social media and other websites are “truthful and non-misleading.” As part of the initiative, the FDA promised to send 100 letters to companies with deceptive ads.The new FDA letters each contain “cease and desist” language. That’s a different approach for the agency, which typically drafts its letters in highly bureaucratic language citing specific FDA regulations.Hims has been under scrutiny from Washington for months. Earlier this year, a Super Bowl ad from the company touted the benefits of its weight-loss medications but didn’t list any of their side effects or potential harms. FDA rules require advertisements to present a balanced picture of drug risks and benefits.Makary singled out the ad in last week’s Journal of the American Medical Association, calling it a “brazen” example of how advertising is “contributing to America’s culture of overreliance on pharmaceuticals for health.”San Francisco-based Hims did not immediately respond to requests for comment Tuesday morning.Hims and similar companies initially sold cheap generic versions of drugs for hair loss, erectile dysfunction and other health issues. But booming demand for obesity medications opened the door to selling cheaper copies.The letters posted Tuesday come from FDA’s drug center. The agency's assertive approach follows longstanding concerns over the ethical implications of pharmaceutical advertising, particularly how it shapes public perceptions and affects patient behaviors.
